相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Viral vectors for therapy of neurologic diseases
Sourav R. Choudhury et al.
NEUROPHARMACOLOGY (2017)
Optogenetic Stimulation of Frontal D1 Neurons Compensates for Impaired Temporal Control of Action in Dopamine-Depleted Mice
Young-Cho Kim et al.
CURRENT BIOLOGY (2017)
RNAi prevents and reverses phenotypes induced by mutant human ataxin-1
Megan S. Keiser et al.
ANNALS OF NEUROLOGY (2016)
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era
Naomi P. Visanji et al.
TRENDS IN NEUROSCIENCES (2016)
Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons
D. Caudal et al.
EXPERIMENTAL NEUROLOGY (2015)
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model
Alevtina D. Zharikov et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Disease-modifying therapeutic directions for Lewy-Body dementias
Qiang Zhang et al.
FRONTIERS IN NEUROSCIENCE (2015)
Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects
Christina E. Khodr et al.
BRAIN RESEARCH (2014)
Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis
Karina J. Vargas et al.
JOURNAL OF NEUROSCIENCE (2014)
Broad Therapeutic Benefit After RNAi Expression Vector Delivery to Deep Cerebellar Nuclei: Implications for Spinocerebellar Ataxia Type 1 Therapy
Megan S. Keiser et al.
MOLECULAR THERAPY (2014)
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse
Ryan L. Boudreau et al.
NUCLEIC ACIDS RESEARCH (2013)
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease
Nandakumar S. Narayanan et al.
REVIEWS IN THE NEUROSCIENCES (2013)
Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective
Han-Joon Kim
Experimental Neurobiology (2013)
Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity
Meret Nora Gaugler et al.
ACTA NEUROPATHOLOGICA (2012)
α-Synuclein knockout mice have cognitive impairments
V. S. Kokhan et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
Kelvin C. Luk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons
M. Decressac et al.
NEUROBIOLOGY OF DISEASE (2012)
A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (Line 61) Mice
Marie-Francoise Chesselet et al.
NEUROTHERAPEUTICS (2012)
Prefrontal D1 dopamine signaling is required for temporal control
Nandakumar S. Narayanan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
Kelvin C. Luk et al.
SCIENCE (2012)
α-Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Mickael Decressac et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons
Ye Han et al.
BRAIN RESEARCH (2011)
An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons
Christina E. Khodr et al.
BRAIN RESEARCH (2011)
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease
Shuwen Cao et al.
MOLECULAR NEURODEGENERATION (2010)
In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
Oleg S. Gorbatyuk et al.
MOLECULAR THERAPY (2010)
Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis
Venu M. Nemani et al.
NEURON (2010)
α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
Alison L. McCormack et al.
PLOS ONE (2010)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Tests to assess motor phenotype in mice: a user's guide
Simon P. Brooks et al.
NATURE REVIEWS NEUROSCIENCE (2009)
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice
Daniel Alvarez-Fischer et al.
EXPERIMENTAL NEUROLOGY (2008)
Strengths and limitations of genetic mouse models of Parkinson's disease
Marie-Francoise Chesselet et al.
PARKINSONISM & RELATED DISORDERS (2008)
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
Jodi L. McBride et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Real-time quantification of microRNAs by stem-loop RT-PCR
CF Chen et al.
NUCLEIC ACIDS RESEARCH (2005)
α-synuclein locus duplication as a cause of familial Parkinson's disease
MC Chartier-Harlin et al.
LANCET (2004)
Mice lacking α-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration
RE Drolet et al.
NEUROTOXICOLOGY (2004)
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
HB Xia et al.
NATURE MEDICINE (2004)
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein
SM Fleming et al.
JOURNAL OF NEUROSCIENCE (2004)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Insect cells as a factory to produce adeno-associated virus type 2 vectors
M Urabe et al.
HUMAN GENE THERAPY (2002)
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
W Dauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters
E Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein
BI Giasson et al.
NEURON (2002)
Where does Parkinson disease pathology begin in the brain?
K Del Tredici et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
Alpha-synuclein and neurodegenerative diseases
M Goedert
NATURE REVIEWS NEUROSCIENCE (2001)
Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis
Y Tanaka et al.
HUMAN MOLECULAR GENETICS (2001)
Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy
KA Conway et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
A Abeliovich et al.
NEURON (2000)
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease
PM Mattila et al.
ACTA NEUROPATHOLOGICA (2000)
分享论文
